Jimson weed: Difference between revisions

No edit summary
Line 18: Line 18:


==Differential Diagnosis==
==Differential Diagnosis==
#Sympathomimetic toxicity
*Sympathomimetic toxicity
#*Red, dry skin and absent bowel sounds favors anticholinergic toxicity
**Red, dry skin and absent bowel sounds favors anticholinergic toxicity
#Encephalitis
*Encephalitis
#Head trauma
*Head trauma
#ETOH/sedative withdrawal
*ETOH/sedative withdrawal
#[[Neuroleptic Malignant Syndrome (NMS)]]
*[[Neuroleptic Malignant Syndrome (NMS)]]
#Acute psychotic disorder
*Acute psychotic disorder


{{Anticholinergic types}}
{{Anticholinergic types}}

Revision as of 15:33, 17 September 2015

Background

Datura stramonium aka Jimson Weed
  • Contains up to 28 different anticholinergic alkaloids[1]
    • Atropine, hyoscyamine, and scopolamine
  • All parts of the plant are toxic but the highest concentration is in the seeds
    • 50-100 seeds in each pod
    • 100 seeds is the equivalent of about 6 mg atropine
  • Estimated lethal doses of atropine in adults ≥10 mg[2]

Administration

  • Inhalation (smoking dried leaves or other plant parts)
  • Ingestion (eating plant parts or foods containing extracts)

Clinical Features

Differential Diagnosis

  • Sympathomimetic toxicity
    • Red, dry skin and absent bowel sounds favors anticholinergic toxicity
  • Encephalitis
  • Head trauma
  • ETOH/sedative withdrawal
  • Neuroleptic Malignant Syndrome (NMS)
  • Acute psychotic disorder

Anticholinergic toxicity Causes

Diagnosis

Treatment

  • Supportive care and patient reassurance
  • Sedation as needed with benzos
  • In severe cases, physostigmine 0.5–2.0 mg IV at a rate of no more than 1 mg/min (adult dosing)
    • A second dose may be administered if necessary
    • Children should receive 0.02 mg/kg intravenously and the rate should not exceed 0.5 mg/min

See Also

References

  1. Krenzelok EP. Aspects of Datura poisoning and treatment. Clin Tox. 2010; 48(2):104-110.
  2. Shervette RE, et al. Jimson "loco" weed abuse in adolescents. Pediatrics. 1979; 63:520-523.
  3. Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium – theory, evidence and practice. Br J Clin Pharmacol. 2015;81(3):516-24.